Which has better valuation & earnings, NAGE or ODD?

ODDITY Tech has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than ODDITY Tech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Niagen Bioscience $129.42M 1.91 $17.38M $0.18 17.28 ODDITY Tech $809.84M 1.00 $110.75M $0.79 17.89

Does the media favor NAGE or ODD?

In the previous week, ODDITY Tech had 13 more articles in the media than Niagen Bioscience. MarketBeat recorded 18 mentions for ODDITY Tech and 5 mentions for Niagen Bioscience. ODDITY Tech's average media sentiment score of 0.55 beat Niagen Bioscience's score of 0.13 indicating that ODDITY Tech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ODDITY Tech 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HNST or NAGE?

In the previous week, Niagen Bioscience had 4 more articles in the media than Honest. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Honest. Honest's average media sentiment score of 1.89 beat Niagen Bioscience's score of 0.13 indicating that Honest is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Honest 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BWMX or NAGE?

Niagen Bioscience has a consensus price target of $10.33, indicating a potential upside of 232.26%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Betterware de Mexico SAPI de C 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media favor BWMX or NAGE?

In the previous week, Niagen Bioscience had 4 more articles in the media than Betterware de Mexico SAPI de C. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Betterware de Mexico SAPI de C. Betterware de Mexico SAPI de C's average media sentiment score of 0.59 beat Niagen Bioscience's score of 0.13 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Betterware de Mexico SAPI de C 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NAGE or PRE?

In the previous week, Niagen Bioscience had 4 more articles in the media than Prenetics Global. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.86 beat Niagen Bioscience's score of 0.13 indicating that Prenetics Global is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prenetics Global 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate YSG or NAGE?

Niagen Bioscience has a consensus price target of $10.33, suggesting a potential upside of 232.26%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Yatsen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yatsen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media refer more to YSG or NAGE?

In the previous week, Yatsen had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 8 mentions for Yatsen and 5 mentions for Niagen Bioscience. Yatsen's average media sentiment score of 0.15 beat Niagen Bioscience's score of 0.13 indicating that Yatsen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yatsen 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Niagen Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Niagen Bioscience (NAGE) Competitors

$3.11 -0.06 (-1.89%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$3.14 +0.03 (+1.09%)

As of 07:43 AM Eastern

Compare

NAGE vs. ODD, HNST, BWMX, PRE, and YSG

Should you buy Niagen Bioscience stock or one of its competitors? Niagen Bioscience's main competitors and comparable companies include ODDITY Tech (ODD), Honest (HNST), Betterware de Mexico SAPI de C (BWMX), Prenetics Global (PRE), and Yatsen (YSG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Niagen Bioscience compare to ODDITY Tech?

Niagen Bioscience (NASDAQ:NAGE) and ODDITY Tech (NASDAQ:ODD) are both small-cap consumer staples companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, ODDITY Tech had 13 more articles in the media than Niagen Bioscience. MarketBeat recorded 18 mentions for ODDITY Tech and 5 mentions for Niagen Bioscience. ODDITY Tech's average media sentiment score of 0.55 beat Niagen Bioscience's score of 0.13 indicating that ODDITY Tech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ODDITY Tech	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience presently has a consensus price target of $10.33, suggesting a potential upside of 232.26%. ODDITY Tech has a consensus price target of $25.75, suggesting a potential upside of 82.24%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Niagen Bioscience is more favorable than ODDITY Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
ODDITY Tech	4 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.69

15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 35.9% of ODDITY Tech shares are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ODDITY Tech has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than ODDITY Tech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.91	$17.38M	$0.18	17.28
ODDITY Tech	$809.84M	1.00	$110.75M	$0.79	17.89

Niagen Bioscience has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, ODDITY Tech has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to ODDITY Tech's net margin of 6.97%. Niagen Bioscience's return on equity of 17.95% beat ODDITY Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
ODDITY Tech	6.97%	15.38%	4.99%

Summary

Niagen Bioscience beats ODDITY Tech on 9 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Honest?

Honest (NASDAQ:HNST) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Honest presently has a consensus target price of $4.84, suggesting a potential downside of 17.26%. Niagen Bioscience has a consensus target price of $10.33, suggesting a potential upside of 232.26%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Honest.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Honest	2 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.22
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Honest has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Niagen Bioscience has a net margin of 12.39% compared to Honest's net margin of -3.56%. Niagen Bioscience's return on equity of 17.95% beat Honest's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Honest	-3.56%	4.31%	3.33%
Niagen Bioscience	12.39%	17.95%	13.17%

45.5% of Honest shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 9.4% of Honest shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Niagen Bioscience had 4 more articles in the media than Honest. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Honest. Honest's average media sentiment score of 1.89 beat Niagen Bioscience's score of 0.13 indicating that Honest is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Honest	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Niagen Bioscience has lower revenue, but higher earnings than Honest. Honest is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Honest	$371.32M	1.73	-$15.69M	-$0.11	N/A
Niagen Bioscience	$129.42M	1.91	$17.38M	$0.18	17.28

Summary

Niagen Bioscience beats Honest on 12 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Betterware de Mexico SAPI de C (NYSE:BWMX) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Niagen Bioscience has a consensus price target of $10.33, indicating a potential upside of 232.26%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Niagen Bioscience is more favorable than Betterware de Mexico SAPI de C.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Betterware de Mexico SAPI de C	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Betterware de Mexico SAPI de C has higher revenue and earnings than Niagen Bioscience. Betterware de Mexico SAPI de C is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Betterware de Mexico SAPI de C	$14.85B	0.04	$55.37M	$1.83	8.46
Niagen Bioscience	$129.42M	1.91	$17.38M	$0.18	17.28

Niagen Bioscience has a net margin of 12.39% compared to Betterware de Mexico SAPI de C's net margin of 8.35%. Betterware de Mexico SAPI de C's return on equity of 77.89% beat Niagen Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Betterware de Mexico SAPI de C	8.35%	77.89%	11.28%
Niagen Bioscience	12.39%	17.95%	13.17%

12.7% of Betterware de Mexico SAPI de C shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Niagen Bioscience had 4 more articles in the media than Betterware de Mexico SAPI de C. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Betterware de Mexico SAPI de C. Betterware de Mexico SAPI de C's average media sentiment score of 0.59 beat Niagen Bioscience's score of 0.13 indicating that Betterware de Mexico SAPI de C is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Betterware de Mexico SAPI de C	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Betterware de Mexico SAPI de C has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market.

Summary

Niagen Bioscience beats Betterware de Mexico SAPI de C on 11 of the 16 factors compared between the two stocks.

How does Niagen Bioscience compare to Prenetics Global?

Niagen Bioscience (NASDAQ:NAGE) and Prenetics Global (NASDAQ:PRE) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Niagen Bioscience has a net margin of 12.39% compared to Prenetics Global's net margin of -47.43%. Niagen Bioscience's return on equity of 17.95% beat Prenetics Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Niagen Bioscience	12.39%	17.95%	13.17%
Prenetics Global	-47.43%	-21.41%	-15.56%

Niagen Bioscience has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market. Comparatively, Prenetics Global has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

In the previous week, Niagen Bioscience had 4 more articles in the media than Prenetics Global. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Prenetics Global. Prenetics Global's average media sentiment score of 0.86 beat Niagen Bioscience's score of 0.13 indicating that Prenetics Global is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prenetics Global	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Niagen Bioscience currently has a consensus target price of $10.33, suggesting a potential upside of 232.26%. Prenetics Global has a consensus target price of $34.80, suggesting a potential upside of 35.78%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Niagen Bioscience is more favorable than Prenetics Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Prenetics Global	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Niagen Bioscience has higher revenue and earnings than Prenetics Global. Prenetics Global is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Niagen Bioscience	$129.42M	1.91	$17.38M	$0.18	17.28
Prenetics Global	$92.39M	4.68	-$37.71M	-$4.16	N/A

15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 25.0% of Prenetics Global shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Comparatively, 7.8% of Prenetics Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Niagen Bioscience beats Prenetics Global on 13 of the 17 factors compared between the two stocks.

How does Niagen Bioscience compare to Yatsen?

Yatsen (NYSE:YSG) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Niagen Bioscience has lower revenue, but higher earnings than Yatsen. Yatsen is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yatsen	$614.62M	0.36	-$11.56M	-$0.21	N/A
Niagen Bioscience	$129.42M	1.91	$17.38M	$0.18	17.28

15.4% of Niagen Bioscience shares are held by institutional investors. 29.0% of Yatsen shares are held by company insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Niagen Bioscience has a net margin of 12.39% compared to Yatsen's net margin of -4.63%. Niagen Bioscience's return on equity of 17.95% beat Yatsen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yatsen	-4.63%	-7.13%	-5.49%
Niagen Bioscience	12.39%	17.95%	13.17%

In the previous week, Yatsen had 3 more articles in the media than Niagen Bioscience. MarketBeat recorded 8 mentions for Yatsen and 5 mentions for Niagen Bioscience. Yatsen's average media sentiment score of 0.15 beat Niagen Bioscience's score of 0.13 indicating that Yatsen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yatsen	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Niagen Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Niagen Bioscience has a consensus price target of $10.33, suggesting a potential upside of 232.26%. Given Niagen Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Niagen Bioscience is more favorable than Yatsen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yatsen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Yatsen has a beta of -1.54, meaning that its stock price is 254% less volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Summary

Niagen Bioscience beats Yatsen on 13 of the 17 factors compared between the two stocks.

Get Niagen Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAGE vs. The Competition

Export

Metric	Niagen Bioscience	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$252.47M	$23.61B	$15.88B	$12.73B
Dividend Yield	N/A	4.33%	3.20%	8.86%
P/E Ratio	17.28	19.28	13.55	25.25
Price / Sales	1.91	13.15	262,949.19	97.66
Price / Cash	15.63	27.10	57.26	52.26
Price / Book	2.99	2.92	4.59	6.14
Net Income	$17.38M	$1.13B	$836.00M	$349.01M
7 Day Performance	-5.47%	-1.48%	-0.94%	-0.31%
1 Month Performance	-10.37%	-0.73%	-0.55%	0.64%
1 Year Performance	-66.63%	-18.73%	12.07%	14.83%

Niagen Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAGE Niagen Bioscience	3.6857 of 5 stars	$3.11 -1.9%	$10.33 +232.3%	-67.8%	$252.47M	$129.42M	17.28	120
ODD ODDITY Tech	2.4665 of 5 stars	$14.59 +0.4%	$25.39 +74.0%	-76.7%	$839.16M	$739.71M	18.45	342	Upcoming Earnings Analyst Forecast Insider Trade Gap Up
HNST Honest	2.6117 of 5 stars	$5.79 +1.1%	$4.84 -16.3%	+47.7%	$636.81M	$371.32M	N/A	190	Positive News Gap Up
BWMX Betterware de Mexico SAPI de C	3.8771 of 5 stars	$15.94 -1.3%	N/A	+15.0%	$594.55M	$744M	8.71	2,441	Analyst Forecast
PRE Prenetics Global	4.179 of 5 stars	$25.73 -0.2%	$34.80 +35.3%	+216.4%	$435.16M	$92.39M	N/A	1	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAGE) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Competitors

NAGE vs. ODD, HNST, BWMX, PRE, and YSG

How does Niagen Bioscience compare to ODDITY Tech?

Summary

How does Niagen Bioscience compare to Honest?

Summary

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Summary

How does Niagen Bioscience compare to Prenetics Global?

Summary

How does Niagen Bioscience compare to Yatsen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Competitors

NAGE vs. ODD, HNST, BWMX, PRE, and YSG

How does Niagen Bioscience compare to ODDITY Tech?

Does the media favor NAGE or ODD?

Do analysts recommend NAGE or ODD?

Do insiders and institutionals hold more shares of NAGE or ODD?

Which has better valuation & earnings, NAGE or ODD?

Which has more volatility and risk, NAGE or ODD?

Is NAGE or ODD more profitable?

Summary

How does Niagen Bioscience compare to Honest?

Do analysts rate HNST or NAGE?

Which has more volatility & risk, HNST or NAGE?

Is HNST or NAGE more profitable?

Do insiders and institutionals believe in HNST or NAGE?

Does the media refer more to HNST or NAGE?

Which has better valuation and earnings, HNST or NAGE?

Summary

How does Niagen Bioscience compare to Betterware de Mexico SAPI de C?

Do analysts rate BWMX or NAGE?

Which has higher valuation and earnings, BWMX or NAGE?

Is BWMX or NAGE more profitable?

Do insiders and institutionals have more ownership in BWMX or NAGE?

Does the media favor BWMX or NAGE?

Which has more risk & volatility, BWMX or NAGE?

Summary

How does Niagen Bioscience compare to Prenetics Global?

Is NAGE or PRE more profitable?

Which has more risk & volatility, NAGE or PRE?

Does the media prefer NAGE or PRE?

Do analysts rate NAGE or PRE?

Which has stronger valuation & earnings, NAGE or PRE?

Do institutionals and insiders believe in NAGE or PRE?

Summary

How does Niagen Bioscience compare to Yatsen?

Which has preferable valuation & earnings, YSG or NAGE?

Do institutionals & insiders hold more shares of YSG or NAGE?

Is YSG or NAGE more profitable?

Does the media refer more to YSG or NAGE?

Do analysts rate YSG or NAGE?

Which has more risk and volatility, YSG or NAGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAGE vs. The Competition

Niagen Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools